Nexalin Technology Announces Abstract Accepted For Presentation At 2023 Military Health System Research Symposium Validating The Potential Of Its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device For The Treatment Of Mild Traumatic Brain Injury
Portfolio Pulse from Happy Mohamed
Nexalin Technology's abstract on its non-invasive, frequency-based deep-brain stimulation device for treating mild traumatic brain injury (mTBI) has been accepted for presentation at the 2023 Military Health System Research Symposium. The abstract details a study using Magnetoencephalography (MEG) to assess neuronal changes in veterans with combat-related mTBI after treatment with Nexalin's device. The data supports Nexalin's strategy to offer a new tool to treat mTBI without medication or side effects. A prior study also showed significant improvements in patients with chronic insomnia using Nexalin's device.
July 10, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology's abstract acceptance for presentation at a prestigious symposium could boost its reputation and visibility in the medical community. The positive data from the study supports the company's strategy and could potentially lead to increased adoption of its device for treating mTBI and insomnia.
The acceptance of Nexalin's abstract for presentation at a prestigious symposium is a positive development for the company. It not only validates the company's research but also increases its visibility in the medical community. The positive data from the study supports the company's strategy of offering a non-invasive, frequency-based deep-brain stimulation device for treating mTBI and insomnia. This could potentially lead to increased adoption of its device, thereby positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100